Jagadeesan AJ, Murugesan R, Vimala Devi S, Meera M, Madhumala G, Vishwanathan Padmaja M, Ramesh A, Banerjee A, Sushmitha S, Khokhlov AN, et al. Current trends in etiology, prognosis and therapeutic aspects of Parkinson’s disease: a review. Acta Biomed. 2017;88:249–62.

Google Scholar 

Zhao Y, Zhang Y, Zhang J, Yang G. Plasma proteome profiling using tandem mass tag labeling technology reveals potential biomarkers for Parkinson’s disease: a preliminary study. Proteomics Clin Appl. 2022;16: e2100010.

Article  Google Scholar 

Zhao Y, Yang G. Potential of extracellular vesicles in the Parkinson’s disease - Pathological mediators and biomarkers. Neurochem Int. 2021;144: 104974.

Article  Google Scholar 

Politi C, Ciccacci C, Novelli G, Borgiani P. Genetics and Treatment Response in Parkinson’s Disease: An Update on Pharmacogenetic Studies. Neuromolecular Med. 2018;20:1–17.

Article  Google Scholar 

Zhao Y, Zhang Y, Zhang J, Yang G. Salvianolic acid B protects against MPP+-induced neuronal injury via repressing oxidative stress and restoring mitochondrial function. NeuroReport. 2021;32:815–23.

Article  Google Scholar 

Ascherio A, Schwarzschild MA. The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurol. 2016;15:1257–72.

Article  Google Scholar 

Gao XY, Yang T, Gu Y, Sun XH. Mitochondrial Dysfunction in Parkinson’s Disease: From Mechanistic Insights to Therapy. Front Aging Neurosci. 2022;14: 885500.

Article  Google Scholar 

Thapa K, Khan H, Kanojia N, Singh TG, Kaur A, Kaur G. Therapeutic Insights on Ferroptosis in Parkinson’s disease. Eur J Pharmacol. 2022;930:175133.

Article  Google Scholar 

Wang S, Ma F, Huang L, Zhang Y, Peng Y, Xing C, Feng Y, Wang X, Peng Y. Dl-3-n-Butylphthalide (NBP): A Promising Therapeutic Agent for Ischemic Stroke. CNS Neurol Disord Drug Targets. 2018;17:338–47.

Article  Google Scholar 

Huang L, Wang S, Ma F, Zhang Y, Peng Y, Xing C, Feng Y, Wang X, Peng Y. From stroke to neurodegenerative diseases: The multi-target neuroprotective effects of 3-n-butylphthalide and its derivatives. Pharmacol Res. 2018;135:201–11.

Article  Google Scholar 

Xu ZQ, Zhou Y, Shao BZ, Zhang JJ, Liu C. A Systematic Review of Neuroprotective Efficacy and Safety of DL-3-N-Butylphthalide in Ischemic Stroke. Am J Chin Med. 2019;47:507–25.

Article  Google Scholar 

Wang CY, Xu Y, Wang X, Guo C, Wang T, Wang ZY. Dl-3-n-Butylphthalide Inhibits NLRP3 Inflammasome and Mitigates Alzheimer’s-Like Pathology via Nrf2-TXNIP-TrX Axis. Antioxid Redox Signal. 2019;30:1411–31.

Article  Google Scholar 

Chen N, Zhou Z, Li J, Li B, Feng J, He D, Luo Y, Zheng X, Luo J, Zhang J. 3-n-butylphthalide exerts neuroprotective effects by enhancing anti-oxidation and attenuating mitochondrial dysfunction in an in vitro model of ischemic stroke. Drug Des Devel Ther. 2018;12:4261–71.

Article  Google Scholar 

Abdoulaye IA, Guo YJ. A Review of Recent Advances in Neuroprotective Potential of 3-N-Butylphthalide and Its Derivatives. Biomed Res Int. 2016;2016:5012341.

Article  Google Scholar 

Feng X, Peng Y, Liu M, Cui L. DL-3-n-butylphthalide extends survival by attenuating glial activation in a mouse model of amyotrophic lateral sclerosis. Neuropharmacology. 2012;62:1004–10.

Article  Google Scholar 

Zhang D, Zheng N, Fu X, Shi J, Zhang J. Dl-3-n-butylphthalide attenuates myocardial ischemia reperfusion injury by suppressing oxidative stress and regulating cardiac mitophagy via the PINK1/Parkin pathway in rats. J Thorac Dis. 2022;14:1651–62.

Article  Google Scholar 

Que R, Zheng J, Chang Z, Zhang W, Li H, Xie Z, Huang Z, Wang HT, Xu J, Jin D, et al. Dl-3-n-Butylphthalide Rescues Dopaminergic Neurons in Parkinson’s Disease Models by Inhibiting the NLRP3 Inflammasome and Ameliorating Mitochondrial Impairment. Front Immunol. 2021;12: 794770.

Article  Google Scholar 

Xiong N, Huang J, Chen C, Zhao Y, Zhang Z, Jia M, Zhang Z, Hou L, Yang H, Cao X, et al. Dl-3-n-butylphthalide, a natural antioxidant, protects dopamine neurons in rotenone models for Parkinson’s disease. Neurobiol Aging. 2012;33:1777–91.

Article  Google Scholar 

Zhou H, Ye M, Xu W, Yu M, Liu X, Chen Y. DL-3-n-butylphthalide therapy for Parkinson’s disease: A randomized controlled trial. Exp Ther Med. 2019;17:3800–6.

Google Scholar 

Gygi SP, Rochon Y, Franza BR, Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol Cell Biol. 1999;19:1720–30.

Article  Google Scholar 

Liu Q, Zhang B. Integrative Omics Analysis Reveals Post-Transcriptionally Enhanced Protective Host Response in Colorectal Cancers with Microsatellite Instability. J Proteome Res. 2016;15:766–76.

Article  Google Scholar 

Nusinow DP, Szpyt J, Ghandi M, Rose CM, McDonald ER 3rd, Kalocsay M, Jane-Valbuena J, Gelfand E, Schweppe DK, Jedrychowski M, et al. Quantitative Proteomics of the Cancer Cell Line Encyclopedia. Cell. 2020;180(387–402): e316.

Google Scholar 

Mertins P, Tang LC, Krug K, Clark DJ, Gritsenko MA, Chen L, Clauser KR, Clauss TR, Shah P, Gillette MA, et al. Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography-mass spectrometry. Nat Protoc. 2018;13:1632–61.

Article  Google Scholar 

Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, Khainovski N, Pillai S, Dey S, Daniels S, et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics. 2004;3:1154–69.

Article  Google Scholar 

Thompson A, Schafer J, Kuhn K, Kienle S, Schwarz J, Schmidt G, Neumann T, Johnstone R, Mohammed AK, Hamon C. Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. Anal Chem. 2003;75:1895–904.

Article  Google Scholar 

Singh LK, Pandey M, Baithalu RK, Fernandes A, Ali SA, Jaiswal L, Pannu S, Neeraj, Mohanty TK, Kumaresan A, et al. Comparative Proteome Profiling of Saliva Between Estrus and Non-Estrus Stages by Employing Label-Free Quantitation (LFQ) and Tandem Mass Tag (TMT)-LC-MS/MS Analysis: An Approach for Estrus Biomarker Identification in Bubalus bubalis. Front Genet. 2022;13:867909.

Article  Google Scholar 

Rodrigues BM, Mathias LS, Depra IC, Cury SS, de Oliveira M, Olimpio RMC, De Sibio MT, Goncalves BM, Nogueira CR. Effects of Triiodothyronine on Human Osteoblast-Like Cells: Novel Insights From a Global Transcriptome Analysis. Front Cell Dev Biol. 2022;10: 886136.

Article  Google Scholar 

Dhall R, Kreitzman DL. Advances in levodopa therapy for Parkinson disease: Review of RYTARY (carbidopa and levodopa) clinical efficacy and safety. Neurology. 2016;86:S13-24.

Article  Google Scholar 

Calabresi P, Di Filippo M, Ghiglieri V, Tambasco N, Picconi B. Levodopa-induced dyskinesias in patients with Parkinson’s disease: filling the bench-to-bedside gap. Lancet Neurol. 2010;9:1106–17.

Article  Google Scholar 

Fisone G, Bezard E. Molecular mechanisms of l-DOPA-induced dyskinesia. Int Rev Neurobiol. 2011;98:95–122.

Article  Google Scholar 

Li H, Wang H, Zhang L, Wang M, Li Y. Dl-3-n-Butylphthalide Alleviates Behavioral and Cognitive Symptoms Via Modulating Mitochondrial Dynamics in the A53T-alpha-Synuclein Mouse Model of Parkinson’s Disease. Front Neurosci. 2021;15: 647266.

Article  Google Scholar 

Zhu Y, Hou H, Rezai-Zadeh K, Giunta B, Ruscin A, Gemma C, Jin J, Dragicevic N, Bradshaw P, Rasool S, et al. CD45 deficiency drives amyloid-beta peptide oligomers and neuronal loss in Alzheimer’s disease mice. J Neurosci. 2011;31:1355–65.

Article  Google Scholar 

Tan J, Town T, Mori T, Wu Y, Saxe M, Crawford F, Mullan M. CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase. J Neurosci. 2000;20:7587–94.

Article  Google Scholar 

Bottero V, Santiago JA, Potashkin JA. PTPRC Expression in Blood is Downregulated in Parkinson’s and Progressive Supranuclear Palsy Disorders. J Parkinsons Dis. 2018;8:529–37.

Article  Google Scholar 

Wen L, Marki A, Wang Z, Orecchioni M, Makings J, Billitti M, Wang E, Suthahar SSA, Kim K, Kiosses WB, et al. A humanized beta2 integrin knockin mouse reveals localized intra- and extravascular neutrophil integrin activation in vivo. Cell Rep. 2022;39: 110876.

Article  Google Scholar 

Shu J, Li N, Wei W, Zhang L. Detection of molecular signatures and pathways shared by Alzheimer’s disease and type 2 diabetes. Gene. 2022;810: 146070.

Article  Google Scholar 

Gupta R, Kumar P. CREB1(K292) and HINFP(K330) as Putative Common Therapeutic Targets in Alzheimer’s and Parkinson’s Disease. ACS Omega. 2021;6:35780–98.

Article  Google Scholar 

Henderson AR, Wang Q, Meechoovet B, Siniard AL, Naymik M, De Both M, Huentelman MJ, Caselli RJ, Driver-Dunckley E, Dunckley T. DNA Methylation and Expression Profiles of Whole Blood in Parkinson’s Disease. Front Genet. 2021;12: 640266.

Article  Google Scholar 

Xue F, Gao L, Chen T, Chen H, Zhang H, Wang T, Han Z, Gao S, Wang L, Hu Y, et al. Parkinson’s Disease rs117896735 Variant Regulates INPP5F Expression in Brain Tissues and Increases Risk of Alzheimer’s Disease. J Alzheimers Dis. 2022;89(1):67–77.

Article  Google Scholar 

Liu Q, Sasaki T, Kozieradzki I, Wakeham A, Itie A, Dumont DJ, Penninger JM. SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival. Genes Dev. 1999;13:786–91.

Article  Google Scholar 

Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol. 2007;8:275–83.

Article  Google Scholar 

Wawryk-Gawda E, Chylinska-Wrzos P, Lis-Sochocka M, Chlapek K, Bulak K, Jedrych M, Jodlowska-Jedrych B. P53 protein in proliferation, repair and apoptosis of cells. Protoplasma. 2014;251:525–33.

Article  Google Scholar 

Liu X, Fan L, Lu C, Yin S, Hu H. Functional Role of p53 in the Regulation of Chemical-Induced Oxidative Stress. Oxid Med Cell Longev. 2020;2020:6039769.

Google Scholar 

Luo Q, Sun W, Wang YF, Li J, Li DW. Association of p53 with Neurodegeneration in Parkinson’s Disease. Parkinsons Dis. 2022;2022:6600944.

Google Scholar 

Qi X, Davis B, Chiang YH, Filichia E, Barnett A, Greig NH, Hoffer B, Luo Y. Dopaminergic neuron-specific deletion of p53 gene is neuroprotective in an experimental Parkinson’s disease model. J Neurochem. 2016;138:746–57.

Article  Google Scholar 

Jeffers JR, Parganas E, Lee Y, Yang C, Wang J, Brennan J, MacLean KH, Han J, Chittenden T, Ihle JN, et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell. 2003;4:321–8.

Article  Google Scholar 

Shibue T, Takeda K, Oda E, Tanaka H, Murasawa H, Takaoka A, Morishita Y, Akira S, Taniguchi T, Tanaka N. Integral role of Noxa in p53-mediated apoptotic response. Genes Dev. 2003;17:2233–8.

Article  Google Scholar 

Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995;80:293–9.

Article  Google Scholar 

Karim MR, Liao EE, Kim J, Meints J, Martinez HM, Pletnikova O, Troncoso JC, Lee MK. alpha-Synucleinopathy associated c-Abl activation causes p53-dependent autophagy impairment. Mol Neurodegener. 2020;15:27.

Article